{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:48:14Z","timestamp":1761058094940},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1993,9,1]],"date-time":"1993-09-01T00:00:00Z","timestamp":746841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[1993,9]]},"DOI":"10.1007\/bf00315497","type":"journal-article","created":{"date-parts":[[2004,10,20]],"date-time":"2004-10-20T08:05:21Z","timestamp":1098259521000},"page":"151-156","source":"Crossref","is-referenced-by-count":5,"title":["Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine"],"prefix":"10.1007","volume":"45","author":[{"given":"A.","family":"Mescheder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Kirch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2362.1992.tb01929.x","volume":"22","author":"H Hinrichsen","year":"1992","unstructured":"Hinrichsen H, Halabi A, Kirch W (1992) Haemodynamic effects of H2-receptor antagonists. Eur J Clin Invest 22: 9?18","journal-title":"Eur J Clin Invest"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/j.1552-4604.1989.tb03365.x","volume":"29","author":"DG Hughes","year":"1989","unstructured":"Hughes DG, Dowling EA, DeMeersman RE, Garnett WR, Karnes HT (1989) Cardiovascular effects of H2-receptor antagonists. J Clin Pharmacol 29: 472?477","journal-title":"J Clin Pharmacol"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/0016-5085(89)90503-9","volume":"96","author":"W Kirch","year":"1989","unstructured":"Kirch W, Halabi A, Linde M, Santos SR, Ohnhaus EE (1989) Negative effects of famotidine on cardiac performance assessed by noninvasive hemodynamic measurements. Gastroenterology 96: 1388?1392","journal-title":"Gastroenterology"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.1991.69","volume":"49","author":"P Salmon","year":"1991","unstructured":"Salmon P, Fitzgerald D, Kenny M (1991) No effect of famotidine on cardiac performance by noninvasive hemodynamic measurements. Clin Pharmacol Ther 49: 589?595","journal-title":"Clin Pharmacol Ther"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/clpt.1990.153","volume":"48","author":"H Hinrichsen","year":"1990","unstructured":"Hinrichsen H, Halabi A, Kirch W (1990) Hemodynamic effects of different H2-receptor antagonists. Clin Pharmacol Ther 48: 302?308","journal-title":"Clin Pharmacol Ther"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/gut.32.6.630","volume":"32","author":"A Halabi","year":"1991","unstructured":"Halabi A, Kirch W (1991) Negative chronotropic effects of nizatidine. Gut 32: 630?634","journal-title":"Gut"},{"key":"CR7","first-page":"433","volume":"66","author":"R Erbel","year":"1977","unstructured":"Erbel R, Belz GG (1977) Untersuchungen zur Messmethode der systolischen Zeitintervalle. Z Kardiol 66: 433?435","journal-title":"Z Kardiol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00005344-199007000-00011","volume":"16","author":"A Halabi","year":"1990","unstructured":"Halabi A, Endell W, Halabi I, Kirch W (1990) Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. J Cardiovasc Pharmacol 16: 81?86","journal-title":"J Cardiovasc Pharmacol"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0002-9149(69)90012-5","volume":"23","author":"AM Weissler","year":"1969","unstructured":"Weissler AM, Harris WS, Schoenfeld CD (1969) Bedside technics for the evaluation of ventricular function in man. Am J Cardiol 23: 577?583","journal-title":"Am J Cardiol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-2008-1070636","volume":"105","author":"H Kuhn","year":"1980","unstructured":"Kuhn H, Loogen F (1980) Die Bestimmung der systolischen Zeitintervalle. Dtsch Med Wochenschr 105: 214?218","journal-title":"Dtsch Med Wochenschr"},{"key":"CR11","first-page":"1208","volume":"37","author":"WG Kubicek","year":"1966","unstructured":"Kubicek WG, Karnegis JN, Patterson RP, Witsoe DA, Mattson RM (1966) Development and evaluation of an impedance cardiac output system. Aerospace Med 37: 1208?1212","journal-title":"Aerospace Med"},{"key":"CR12","first-page":"221","volume":"5","author":"M Linde","year":"1990","unstructured":"Linde M, Halabi A, Kirch W (1990) Einsatzm\u00f6glichkeiten der Impedanzkardiographie f\u00fcr h\u00e4modynamische Fragestellungen in der klinischen Pharmakologie. Cor Vasa 5: 221?225","journal-title":"Cor Vasa"},{"key":"CR13","first-page":"863","volume":"67","author":"C Stick","year":"1978","unstructured":"Stick C (1978) The reproducibility of stroke-volume measurements by impedance cardiography. Z Kardiol 67: 863?867","journal-title":"Z Kardiol"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1159\/000470537","volume":"4","author":"K Breithaupt","year":"1990","unstructured":"Breithaupt K, Erb K, Neumann B, Wolf GK, Belz GG (1990) Comparison of four noninvasive techniques to measure stroke volume; dual beam Doppler echoaortography, electrical impedance cardiography, mechanosphygmography, and M-mode echocardiography on the left ventricle. Am J Noninvas Cardiol 4: 203?209","journal-title":"Am J Noninvas Cardiol"},{"key":"CR15","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4612-5246-7","volume-title":"Applied statistics","author":"L Sachs","year":"1984","unstructured":"Sachs L (1984) Applied statistics, 2nd edn. Springer, Berlin Heidelberg New York","edition":"2nd edn."},{"key":"CR16","volume-title":"BMDP Statistical Software Manual, vols. 1\/2","author":"WJ Dixon","year":"1988","unstructured":"Dixon WJ (1988) BMDP Statistical Software Manual, vols. 1\/2. University of California Press, Berkeley"},{"key":"CR17","first-page":"4","volume":"266","author":"RG Pendleton","year":"1983","unstructured":"Pendleton RG, Torchiana ML, Chung C, Cook P, Wiese S, Clineschmidt BV (1983) Studies on MK-208 (YM-11 170) a new, slowly dissociable H2-receptor antagonist. Arch Int Pharmacodyn 266: 4?16","journal-title":"Arch Int Pharmacodyn"},{"key":"CR18","volume-title":"Therapeutic drugs, vols. 1\/2","author":"C Dollery","year":"1991","unstructured":"Dollery C (1991) Therapeutic drugs, vols. 1\/2, 1st edn. Churchill Livingstone, Edinburgh","edition":"1st edn."},{"key":"CR19","first-page":"240","volume":"39","author":"K Bemis","year":"1989","unstructured":"Bemis K, Bendele A, Clemens J, Deldar A, Gidda J, Hamelink J, Holland D, Lamishaw B, McGrath J, Shannon H, Smallwood J, Williams PD (1989) General pharmacology of nizatidine in animals. Arzneimittelforschung\/Drug Res 39: 240?250","journal-title":"Arzneimittelforschung\/Drug Res"},{"issue":"136","key":"CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00365528709094479","volume":"22","author":"DM Morton","year":"1987","unstructured":"Morton DM (1987) Pharmacology and toxicology of nizatidine. Scand J Gastroenterol 22 [Suppl 136]: 1?8","journal-title":"Scand J Gastroenterol"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1023\/A:1015994607652","volume":"6","author":"JW Kosh","year":"1989","unstructured":"Kosh JW, Sowell JW, Chapman JM (1989) A comparison of the cholinergic activity of selected H2-antagonists and sulfoxide metabolites. Pharm Res 6: 709?713","journal-title":"Pharm Res"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(83)92605-3","volume":"I","author":"WE Hansen","year":"1983","unstructured":"Hansen WE, Bertl S (1983) Inhibition of cholinesterases by ranitidine. Lancet I: 235","journal-title":"Lancet"},{"key":"CR23","series-title":"Medicine Publishing Foundation Series","first-page":"187","volume-title":"The clinical use of ranitidine","author":"EJS Boyd","year":"1982","unstructured":"Boyd EJS, Wilson JA, Peden NR, Wormsley KG (1982) Maintenance treatment of duodenal ulcer with ranitidine. In: Misiewicz JJ, Wormsley KG (eds) The clinical use of ranitidine. (Medicine Publishing Foundation Series 5). Medicine Publishing Foundation, Oxford, pp 187?189"},{"key":"CR24","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0735-1097(87)80120-1","volume":"10","author":"C Vigorito","year":"1987","unstructured":"Vigorito C, Giordano A, De Caprio L, Vitale DF, Maurea N, Silvestri P, Tuccillo B, Ferrara N, Marone G, Rengo F (1987) Effects of histamine on coronary hemodynamics in humans: role of H1 and H2 receptors. J Am Coll Cardiol 10: 1207?1213","journal-title":"J Am Coll Cardiol"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/01.RES.61.2.280","volume":"61","author":"N Toda","year":"1987","unstructured":"Toda N (1987) Mechanism of histamine actions in human coronary arteries. Circ Res 61: 280?286","journal-title":"Circ Res"},{"key":"CR26","first-page":"323","volume":"44","author":"G Morini","year":"1989","unstructured":"Morini G, Chiavarini M, Barocelli E, Impicciatore M (1989) Effects of H2-blockers on rat mesenteric arterioles under resting conditions. Farmaco 44: 323?328","journal-title":"Farmaco"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01964874","volume":"7","author":"D Reinhardt","year":"1977","unstructured":"Reinhardt D, Schmidt U, Brodde OE, Sch\u00fcmann HJ (1977) H1- and H2-receptor mediated responses to histamine on contractility and cyclic AMP of atrial and papillary muscles from guinea-pig hearts. Agents Actions 7: 1?12","journal-title":"Agents Actions"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/B978-0-7236-0589-8.50010-7","volume-title":"Pharmacology of histamine receptors","author":"CL Johnson","year":"1982","unstructured":"Johnson CL (1982) Histamine receptors and cyclic nucleotides. In: Ganellin CR, Parsons ME (eds) Pharmacology of histamine receptors. Wright, London, pp 146?216"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/clpt.1992.29","volume":"51","author":"W Kirch","year":"1992","unstructured":"Kirch W, Halabi A, Hinrichsen H (1992) Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clin Pharmacol Ther 51: 325?333","journal-title":"Clin Pharmacol Ther"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/BF01990372","volume":"39","author":"G Coruzzi","year":"1983","unstructured":"Coruzzi G, Poli E, Fesani F, Medici D, Bertaccini G (1983) Negative inotropic effect of some H2-receptor antagonists on the isolated human atria. Experientia 39: 1284?1286","journal-title":"Experientia"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.1982.76","volume":"31","author":"GG Belz","year":"1982","unstructured":"Belz GG, Doering W, Aust PE, Heinz M, Matthews J, Schneider B (1982) Quinidine-digoxin interaction: cardiac efficacy of elevated serum digoxin concentrations. Clin Pharmacol Ther 31: 548?554","journal-title":"Clin Pharmacol Ther"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF00542455","volume":"22","author":"GG Belz","year":"1982","unstructured":"Belz GG, Aust PE, Doering W, Heinz M, Schneider B (1982) Pharmacodynamics of a single dose of quinidine during chronic digoxin treatment. A double blind placebo and sparteine-controlled crossover study. Eur J Clin Pharmacol 22: 117?122","journal-title":"Eur J Clin Pharmacol"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/BF01966204","volume":"19","author":"G Bertaccini","year":"1986","unstructured":"Bertaccini G, Coruzzi G, Poli E, Adami M (1986) Pharmacology of the novel H2 antagonist famotidine: in vitro studies. Agents Actions 19: 180?187","journal-title":"Agents Actions"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00315497.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00315497\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00315497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T19:08:54Z","timestamp":1554318534000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00315497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,9]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1993,9]]}},"alternative-id":["BF00315497"],"URL":"https:\/\/doi.org\/10.1007\/bf00315497","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,9]]}}}